Get the Stockscreener App
17.53
1.74%
-0.31
Pre-market:
17.04
-0.49
-2.80%
10 X Genomics Inc stock is traded at $17.53, with a volume of 2.68M.
It is down -1.74% in the last 24 hours and up +2.63% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$17.84
Open:
$17.69
24h Volume:
2.68M
Relative Volume:
0.96
Market Cap:
$2.22B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-8.6782
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-1.90%
1M Performance:
+2.63%
6M Performance:
+64.60%
1Y Performance:
+8.54%
1-Day Range:
$17.41
$18.38
1-Week Range:
$17.06
$18.38
52-Week Range:
$6.78
$20.34
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
17.53 | 2.26B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
229.16 | 38.14B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
75.07 | 13.50B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
45.04 | 8.50B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
95.73 | 7.97B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
35.20 | 6.39B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics $TXG Shares Bought by Jump Financial LLC - MarketBeat
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders - Finviz
Why 10x Genomics Inc. stock appeals to analystsMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Russell Investments Group Ltd. Increases Stock Position in 10x Genomics $TXG - MarketBeat
Is 10x Genomics Inc. (1KJ) stock among top earnings playsJuly 2025 Highlights & Low Risk Entry Point Tips - Newser
Market Fear: Is CPSR stock trading at a premium valuation2025 Performance Recap & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus
TXG: Morgan Stanley Downgrades 10x Genomics, Raises Price Target - GuruFocus
Tumor Transcriptomics Research Report 2025: An $8.71 Billion Market by 2030, Driven by Rising Global Cancer Prevalence and Advancements in Genomic Sequencing Technologies - GlobeNewswire Inc.
TXG Technical Analysis & Signals — Is 10x Genomics, Inc. Stock a Buy or Sell? - Meyka
Is 10x Genomics Inc. stock safe for conservative investors2025 Breakouts & Breakdowns & Weekly Return Optimization Alerts - BỘ NỘI VỤ
Aug Levels: Why 10x Genomics Inc. stock could benefit from AI revolutionJuly 2025 Institutional & Verified Technical Trade Signals - BỘ NỘI VỤ
What sentiment indicators say about 10x Genomics Inc. stockQuarterly Profit Summary & Reliable Breakout Forecasts - BỘ NỘI VỤ
10x Genomics to Acquire Scale Biosciences (PR Newswire) - Aktiellt
Buy Signal: Is 10x Genomics Inc. stock safe for conservative investorsWeekly Earnings Recap & Reliable Momentum Entry Alerts - BỘ NỘI VỤ
How 10x Genomics Inc. stock responds to policy changes2025 Volatility Report & Risk Managed Trade Strategies - BỘ NỘI VỤ
10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing - marketscreener.com
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
Pres Hindson Surrenders 8,283 Of 10X Genomics Inc [TXG] - TradingView
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know - Finviz
CEO Saxonov Files To Sell 13,096 Of 10X Genomics Inc [TXG] - TradingView
CFO Taich Files To Sell 11,312 Of 10X Genomics Inc [TXG] - TradingView
Q3 2025 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN
10x Genomics, Inc.Common Stock (NQ: TXG - Markets Financial Content
Is 10x Genomics’ (TXG) New Asia-Pacific Consortium Key to Sustaining Its Leadership in Spatial Genomics? - Yahoo Finance
10x Genomics (TXG) Price Target Increased by 10.47% to 16.66 - MSN
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know - Yahoo Finance
10X Genomics stock hits 52-week high at 17.7 USD By Investing.com - Investing.com India
10X Genomics stock hits 52-week high at 17.7 USD - Investing.com
Spatial Biology Market Analysis and Forecast, 2025-2035: - GlobeNewswire
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
How 10x Genomics Inc. (1KJ) stock trades pre earnings2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Total liabilities & shareholders' equities of 10x Genomics Inc Class A – HAM:1KJ - TradingView
Is 10x Genomics Inc. stock a buy before product launchesJuly 2025 Closing Moves & Safe Entry Zone Tips - newser.com
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium - StreetInsider
3 Reasons to Avoid TXG and 1 Stock to Buy Instead - Yahoo Finance
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
TXG (10x Genomics) Inventory-to-Revenue : 0.44 (As of Sep. 2025) - GuruFocus
10x Genomics Announces Chief Legal Officer Retirement - The Globe and Mail
10x Genomics GC Who Led Rule Of Law Effort To Retire In '26 - Law360
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump - simplywall.st
10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026 - MarketScreener
10X Genomics Stock Soars 17.31%, Hits Intraday High of $15.26 - Markets Mojo
10x Genomics Inc Class A Earnings and Revenue – HAM:1KJ - TradingView
How 10x Genomics Inc. (1KJ) stock valuation compares with sectorChart Signals & Safe Entry Point Alerts - newser.com
Why 10x Genomics Inc. (1KJ) stock attracts wealthy investorsSell Signal & Verified Stock Trade Ideas - newser.com
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 - Eastern Progress
TXG announces CLO retirement; Randy Wu to serve as General Counsel - Stock Titan
10x Genomics, Inc. (TXG) Stock Price Quote Today & Current Price Chart - Capital.com
10x Genomics (TXG): Assessing Valuation After Strong Earnings, Upbeat Forecast and New Product Launch - Yahoo Finance
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
Nov 24 '25 |
Sale |
19.00 |
8,283 |
157,363 |
432,605 |
| Saxonov Serge | Chief Executive Officer |
Nov 24 '25 |
Sale |
19.00 |
13,261 |
251,936 |
1,021,556 |
4.47%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):